BioCardia, Inc. (BCDA) Stock Price & Analysis
BioCardia, Inc. (BCDA) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $0.7726 (+0.08%), as of the Nov 19, 2026 trading session; market cap $11.7M.
Educational signal · not a buy or sell recommendation · How to read this
BioCardia, Inc. · BCDA · NASDAQ
BioCardia, Inc. is a clinical-stage biotechnology company focused on regenerative medicine, particularly in developing advanced cellular therapies for cardiac and respiratory conditions. The company is known for its CardiAMP Cell Therapy System, which addresses heart failure and chronic myocardial ischemia.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · BioCardia (BCDA)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet, weak growth and an expensive valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Fading; Momentum: Quiet.
- EPS beat 5 of the last 8 reports
Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 28 | Weak | |
| 27 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 29 | Weak | |
| 29 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.7726 | |
| Change on the day | +0.08% | |
| Market capitalisation | $11.7M | — |
| Shares traded on the day | 157.3K |
Price & events
Other perspectives
Council score for BioCardia (BCDA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 25, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is BioCardia (BCDA), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. BioCardia, Inc. (BCDA) is listed on NASDAQ. It employs 17 people. The market values it at $11.7M.
What do the latest results show for BioCardia (BCDA)?
Short answer · as of
Against analyst estimates the company has EPS beat 5 of the last 8 reports.
What are the financial strengths and risks for BioCardia (BCDA)?
Short answer · as of
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth. The distress and quality screens read Piotroski F 1. Trailing ratios: current ratio 1.11 · earnings yield -61.0% · free-cash-flow yield -60.6%.
Data-derived red flags
- Listing risk — at $0.7726 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at BioCardia (BCDA)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $50,000 · EPS -0.59 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for BCDA.
Checked against the records this page reads, on the dates shown above.
How does BioCardia compare with its peers?
Short answer
BioCardia's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $349.21 Nov 19, 2026 | $5.07T | 92 5-pillar Nov 18, 2026 | |
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $58.34 Nov 19, 2026 | $119B | 85 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $168.98 Nov 18, 2026 | $210B | 72 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| BioCardia (BCDA) — this page | $0.7726 | $11.7M | 29 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $50,000
- EPS estimate
- $-0.59
Measured against a quoted price of $0.7726 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 16, 2026
- Transactions
- 35
- Identified insiders
- 9
- Purchases
- 20
- Sales
- 0
- Other transactions
- 15
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BCDA in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BCDA in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about BioCardia (BCDA)?
- BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter
- BioCardia Receives FDA Acceptance For Its Pre-Submission Package For Marketing Clearance Of Its Helix Catheter For Therapeutic And Diagnostic Agent Delivery
- BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
- BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
Investor Questions: BCDA Stock
These answers are editorial: 1 of these 9 answers is drawn from the BCDA research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for BCDA?
BCDA carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is BCDA a good stock to buy?
Stock Expert AI does not rate BCDA buy, sell or hold. BioCardia, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BCDA stock price today?
The last price recorded for BioCardia, Inc. (BCDA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does BioCardia, Inc. navigate regulatory approval processes?
BioCardia, Inc. navigates regulatory approval processes by adhering to stringent guidelines set forth by the FDA and other regulatory bodies.
What are the key factors to evaluate for BCDA?
BioCardia, Inc. (BCDA) holds a MoonshotScore in the low range. Analysts target $15.50 (+1906%). No dividend yield as the company reinvests earnings into R&D. Not financial advice.
How frequently does BCDA data refresh on this page?
BCDA's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BCDA's recent stock price performance?
BioCardia, Inc. (BCDA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline with the CardiAMP Cell Therapy System. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BCDA overvalued or undervalued right now?
BioCardia, Inc. (BCDA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BCDA?
Fractional-share availability for BioCardia, Inc. (BCDA) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 6 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com